| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $585 | 1 | 20 |
Sells | $905,414 | 4 | 80 |
| Murphy Nicole | Head of Pharm Ops and Tech | 1 | $585 | 0 | $0 | $585 |
| Minor Lloyd | director | 0 | $0 | 2 | $239,750 | $-239,750 |
| Singhal Priya | Head of Development | 0 | $0 | 2 | $665,664 | $-665,664 |
Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. For spinal muscular atrophy (SMA), Biogen provides SPINRAZA, while FUMADERM is available for the treatment of plaque psoriasis. Among its other key offerings is ADUHELM, specifically developed for …
Over the last 12 months, insiders at Biogen Inc. have bought $585 and sold $905,414 worth of Biogen Inc. stock.
On average, over the past 5 years, insiders at Biogen Inc. have bought $84,467 and sold $1.58M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Murphy Nicole (Head of Pharm Ops and Tech) — $585.
The last purchase of 3 shares for transaction amount of $585 was made by Murphy Nicole (Head of Pharm Ops and Tech) on 2026‑02‑12.
| 2026-08-04 | Sale | Minor Lloyd | director | 593 0.0004% | $200.96 | $119,169 | +6.27% | |
| 2026-08-03 | Sale | Minor Lloyd | director | 593 0.0004% | $203.34 | $120,581 | +9.75% | |
| 2026-02-12 | Murphy Nicole | Head of Pharm Ops and Tech | 3 <0.0001% | $195.03 | $585 | +2.12% | ||
| 2026-02-09 | Sale | Singhal Priya | Head of Development | 2,660 0.0019% | $199.83 | $531,548 | +2.86% | |
| 2026-02-02 | Sale | Singhal Priya | Head of Development | 748 0.0005% | $179.30 | $134,116 | +11.19% | |
| 2025-09-02 | Sale | Singhal Priya | Head of Development | 517 0.0003% | $133.55 | $69,045 | +31.76% | |
| 2025-07-08 | Sale | Izzar Rachid | Head of Global Product Strat. | 2,223 0.0015% | $135.00 | $300,105 | +31.17% | |
| 2025-05-19 | Sale | Singhal Priya | Head of Development | 3,806 0.0025% | $126.25 | $480,508 | +27.26% | |
| 2025-05-02 | DORSA CAROLINE | director | 1,235 0.0008% | $122.72 | $151,559 | +24.78% | ||
| 2025-03-07 | Sale | SHERWIN STEPHEN A | director | 8,760 0.0059% | $150.02 | $1.31M | -5.97% | |
| 2024-12-09 | Sale | Singhal Priya | Head of Development | 110 <0.0001% | $157.21 | $17,293 | -10.50% | |
| 2024-09-03 | Sale | Singhal Priya | Head of Development | 431 0.0003% | $204.22 | $88,019 | -31.28% | |
| 2024-04-02 | Sale | Singhal Priya | Head of Development | 93 <0.0001% | $213.09 | $19,817 | -8.11% | |
| 2024-02-22 | Sale | Singhal Priya | Head of Development | 262 0.0002% | $221.23 | $57,962 | -9.78% | |
| 2024-02-16 | Sale | Singhal Priya | Head of Development | 108 <0.0001% | $221.49 | $23,921 | -8.00% | |
| 2024-02-15 | Rowinsky Eric K | director | 455 0.0003% | $222.54 | $101,256 | -9.74% | ||
| 2024-02-12 | Sale | Singhal Priya | Head of Development | 419 0.0003% | $239.45 | $100,330 | -17.50% | |
| 2024-02-02 | Sale | Singhal Priya | Head of Development | 634 0.0004% | $245.93 | $155,920 | -16.35% | |
| 2023-12-11 | Sale | Singhal Priya | Head of Development | 110 <0.0001% | $248.00 | $27,280 | -11.89% | |
| 2023-09-05 | Sale | Singhal Priya | Head of Development | 431 0.0003% | $269.43 | $116,124 | -14.37% |
| Murphy Nicole | Head of Pharm Ops and Tech | 19611 0.0133% | $4.88M | 1 | 0 | |
| DENNER ALEXANDER J | director | 643000 0.435% | $160.06M | 12 | 4 | +0.39% |
| Vounatsos Michel | Chief Executive Officer | 34810 0.0235% | $8.67M | 5 | 0 | +8.6% |
| DORSA CAROLINE | director | 27842 0.0188% | $6.93M | 9 | 2 | +27.88% |
| Rowinsky Eric K | director | 20629 0.014% | $5.14M | 1 | 6 | <0.0001% |
| PAPADOPOULOS STELIOS | director | 5000 0.0034% | $1.24M | 1 | 2 | <0.0001% |
| Mantas Jesus B | director | 2943 0.002% | $732,600.99 | 1 | 0 | +1.75% |
$1,927,310,793 | 31 | 28.02% | $1,325.87B | |
Biogen Inc. (BIIB) | $364,368,632 | 29 | 9.65% | $36.8B |
$6,224,380 | 25 | 3.58% | $640.75B | |
$23,541,811 | 22 | 6.43% | $126.14B | |
$28,542,809 | 19 | 26.39% | $505.4B |
| Increased Positions | 512 | +52.51% | 20M | +15% |
| Decreased Positions | 391 | -40.1% | 13M | -9.58% |
| New Positions | 183 | New | 5M | New |
| Sold Out Positions | 85 | Sold Out | 1M | Sold Out |
| Total Postitions | 1,096 | +12.41% | 140M | +5.42% |
| Vanguard Group Inc | $3.07M | 11.76% | 17.29M | -1,416 | <0.01% | 2025-09-30 |
| Primecap Management Co/Ca/ | $2.66M | 10.17% | 14.95M | -847,425 | -5.36% | 2025-09-30 |
| Blackrock, Inc. | $2.63M | 10.04% | 14.76M | +1M | +8.91% | 2025-09-30 |
| State Street Corp | $1.3M | 4.98% | 7.32M | -149,058 | -2% | 2025-09-30 |
| Wellington Management Group Llp | $755,113.00 | 2.89% | 4.25M | -551,916 | -11.5% | 2025-09-30 |
| Geode Capital Management, Llc | $723,511.00 | 2.77% | 4.07M | +150,631 | +3.84% | 2025-09-30 |
| Point72 Asset Management, L.P. | $688,679.00 | 2.64% | 3.87M | +41,174 | +1.07% | 2025-09-30 |
| Invesco Ltd. | $429,991.00 | 1.65% | 2.42M | +98,001 | +4.22% | 2025-09-30 |
| Norges Bank | $402,616.00 | 1.54% | 2.26M | -61,022 | -2.62% | 2025-06-30 |
| Morgan Stanley | $400,368.00 | 1.53% | 2.25M | +295,325 | +15.1% | 2025-09-30 |